New findings suggest that smokers may have a better response to tissue plasminogen activator (tPA) for the treatment of stroke than nonsmokers. In the study, smokers had a 4-fold greater chance of ...

Confirmation that earlier treatment with thrombolysis in patients with acute ischemic stroke translates into better outcomes has come from a registry study involving almost 60,000 patients. In the ...

About 87 percent of all strokes are ischemic, meaning they’re caused by a blood clot in the brain. For more than 20 years, the standard of care has been a drug called TPA. But now, some doctors are ...

Use of the "clot-busting" drug tissue plasminogen activator (tPA) to treat patients with strokes caused by a blockage of blood flow nearly doubled between 2003 and 2011. A research team reports both ...

Mann draws attention to 2 important points: (1) stroke outcome depends heavily on initial stroke severity as measured by the National Institutes of Health Stroke Scale (NIHSS), and (2) baseline ...

An experimental therapy using tiny bubbles activated by transcranial doppler ultrasound combined with the clot busting drug tissue plasminogen activator (tPA) is more effective than tPA alone in ...

Even when its clot-dissolving powers are removed, the stroke drug tPA can still protect brain cells from the loss of oxygen and glucose induced by a stroke, researchers have discovered. The finding ...

FRESNO, Calif. (KFSN) -- Stroke is the third leading cause of death in the U.S. claiming the lives of more than 140,000 Americans each year. But many lives could be spared if treatment was given ...

In Europe, use of intravenous tissue plasminogen activator (tPA) in patients older than 80 years is discouraged because these patients have been excluded from certain past clinical trials. A new ...

Twenty years ago stroke doctors celebrated the arrival of a powerful new weapon: the clot-clearing drug tPA. It was hailed as a lifesaver and has proved to be one for hundreds of thousands of patients ...

(HealthDay News) — Blacks, Hispanics, women, seniors on Medicare, and patients in rural areas are less likely to be treated with tissue plasminogen activator (tPA) after stroke, according to research ...